|
|
Post by mango on May 7, 2019 19:10:08 GMT -5
OK I just read the transcript and I apologize for what I said about them hiding the eagle scripts, clearly that is not what Mike was talking about he was talking about the commercial ..running them for a few weeks stopping running them for a few more weeks..that’s what they have to analyze and that’s where some of the symphony numbers are missing from, it had nothing to do with the eagle pharmacy. And Mike even concluded that we need a new different commercial :-) It's truly disappointing that Mannkind spent $9.3M on a TV campaign for the CEO to conclude that we need a new different commercial. :-( Live, learn, grow. That `s the flow. |
|
|
|
Post by falconquest on May 7, 2019 19:17:10 GMT -5
Dumb commercials, dumb comments about market share, arguments over product size, possibility of dilution, Auuggghh, snafu! This is really a nightmare right? I'm going to wake up, still own 28,000 shares and the price will be $15.00. Please tell me that's where we are!
|
|
|
|
Post by awesomo on May 7, 2019 19:32:29 GMT -5
Sooo, I'm guessing the ASM this year isn't going to be quite as optimistic as last year's. Will be interesting to see what kind of tone management sets during the event, Mike sounded pretty deflated during the earnings call.
|
|
|
|
Post by traderdennis on May 7, 2019 19:38:31 GMT -5
Dumb commercials, dumb comments about market share, arguments over product size, possibility of dilution, Auuggghh, snafu! This is really a nightmare right? I'm going to wake up, still own 28,000 shares and the price will be $15.00. Please tell me that's where we are! Probably more likely to wake up and own 2800 shares at $15.00 |
|
|
|
Post by mango on May 7, 2019 19:39:57 GMT -5
I'm going downhill with increasing speed
Compassion gives way, if you listen to greed
Focus on the past and that's what will last
Nothing that is real and nothing you can feel
Focus on tomorrow you'll have to borrow
Images and mind and friends you left behind
Focus on today, you'll find a way
Happiness is how rooting in the now
|
|
|
|
Post by sayhey24 on May 7, 2019 19:57:16 GMT -5
I'm very curious about what Nate Pile is thinking about the call. Will he advise his clients to hold, trim their holdings, or buy more? I have empathy for Mike Castagna. Clearly, the huge expenses in advertising are not yielding the return we all hoped for. I haven't seen an ad, so I cannot comment. But I'm intrigued that so many on the board are not impressed with the ad itself. Perhaps the larger question is what is the realistic timeline between when someone is motivated to follow up on an ad and when that motivation results in additional scripts? Hopefully, the leadership team has a timeframe in mind and has employed marketing experts who know their craft. We've acknowledged provider resistance to innovation as a key factor in addition to insurance pre-authorization hurdles. How to overcome that barrier is a key question. I'm assuming that Mike and the executive team have thought through the challenges and are working on them, but time and money are in short supply; and that is what keeps the short interest so alive and well. Personally, I am of the mind that much of the current agony can be laid at the feet of the FDA, the SEC, and the convicted felon and scumbag, Martin Shkreli. Just of course, IMHO. The delay that resulted from the delayed approval may have proven to be an important factor in the current state of the company. Added to this was Al Mann's passing, poor leadership that missed an opportunity to raise capital with minimal dilution; a change in leadership at Sanofi; and a failure of MNKD management to plan for the possibility that Sanofi would pull the plug. At the end of the day, two things are important to the success of companies: good timing, and good leadership. I believe that in investing, patience is rewarded; but I'm beginning to ask myself: "What is the record for time between a public offering and an acceptable ROI?" I think we might be approaching it. GLTAL Chris C It's fascinating to me just how many negative things have happened to Mannkind. This company can't get a break ever! Now as mnkdfann reports, Mike says: "[W]e do have high market share in people that have been using the drug" Hello? Does this not remind you of the "embarrassment of riches" comment" or the "please call me" about making a deal line? I'm sure Mike meant to say that retention among current users is high but to make the sort of statement he did is just incredulous. As for the ad, think of a park scene where people are enjoying the sunshine and little hamburgers float out of the sky attached to parachutes. Creative perhaps but effective......not so much.
After being around MNKD for a long time I thought today's call was really pretty good. Better than most. IMO, they have turned the corner. As bad as MNKD's luck has been it appears the worst is over and the sun is starting to shine. I remember well Matt's comment about the "embarrassment of riches" and with Al still around he was more right than wrong. The thing is MNKD still has the potential "embarrassment of riches". Mike just needs to closed the deals. The potential is clearly there. Four years after afrezza product launch and afrezza is outperforming all expectations with near zero issues. No SGLT2 or GLP1 can say that. I think of those poor guys losing their balls due to SGLT2 gangrene. With Dr. Kendall on-board he will make head-way in getting SOC changes but it is going to be a slog. I thought Mike's comment about redoing the Affinity 1 and 2 trials the right way for India will be huge once they get the results. I am assuming CGM and connected care will be a key component of the trials. CGM numbers don't lie and the spin doctors will not be able to hide the truth. I see Apple is buying up a number of companies. It will be interesting to see what Tim Cook's plans are for the Apple CGM watch. Its the perfect fit with afrezza and connected care. |
|
|
|
Post by mytakeonit on May 7, 2019 20:15:44 GMT -5
"that's where we are!" I believe that Mike C ran that ad because it had won an award. When you are busy ... it's easy to make a decision a little too fast. So like what everyone has been saying ... Mike C has too much on his plate.
But, that's mytakeonit
|
|
|
|
Post by blueice on May 7, 2019 20:29:48 GMT -5
It's truly disappointing that Mannkind spent $9.3M on a TV campaign for the CEO to conclude that we need a new different commercial. :-( Live, learn, grow. That `s the flow. Wouldn't focus groups be a prudent tool to assess ad viability prior to spending $9M??? |
|
|
|
Post by ezmit on May 7, 2019 20:51:37 GMT -5
People are overreacting to the call. Wasn't especially great but the people that are calling for mc's head don't have a clue. Don't forget the mess he inherited when he became ceo and where we would be without him today. What we are doing here isn't about just selling another drug, we are asking endo's, who have been doing basically the same thing for the last 20 years to try something completely new. Afrezza, is a life altering drug, but one that is deeply misunderstood in the medical community and isn't going to sell itself. EV's didn't sell themselves either. The tech was around decades ago and it is just now getting a strong foothold in the market. Afrezza has nearly 100 years of habit fighting against it along with 3 bp's worth nearly 300 billion(sanofi, novo, eli.) You have reluctant Dr's who have gone complacent by doing the same thing for decades. Patients, who have been injecting for their entire lives unsure about this new treatment. Insurance companies only looking out for the bottom line and rejecting Afrezza regardless of patient outcomes.
BUT, there is progress, albeit not as fast as we would like. listen, we know how good this drug works. We see it all over the place on social media improving peoples lives. It's simply gonna take time. Now, i'm in this for the longhaul, so i'm going to sit back and watch mike and co turn this little snowball into a fucking avalanche.
|
|
|
|
Post by mango on May 7, 2019 20:51:49 GMT -5
Live, learn, grow. That `s the flow. Wouldn't focus groups be a prudent tool to assess ad viability prior to spending $9M??? Is that not what this is? The Universe is on our side (i think)  |
|
|
|
Post by blueice on May 7, 2019 20:56:33 GMT -5
Wouldn't focus groups be a prudent tool to assess ad viability prior to spending $9M??? Is that not what this is? The Universe is on our side (i think) It is but if they did it on a smaller scale, it would have been less costly and time consuming. |
|
|
|
Post by mango on May 7, 2019 21:06:25 GMT -5
Is that not what this is? The Universe is on our side (i think) It is but if they did it on a smaller scale, it would have been less costly and time consuming. All good things In all good time |
|
|
|
Post by wyattdog on May 7, 2019 21:10:43 GMT -5
i heard a lot of good things on this call but is it me or are we turning into stocktwits. oh well who cares i'm in for the long haul and i know who to pay attention to on this board.
|
|
|
|
Post by mnkdfann on May 7, 2019 21:18:46 GMT -5
i heard a lot of good things on this call but is it me or are we turning into stocktwits. oh well who cares i'm in for the long haul and i know who to pay attention to on this board. I won't say I heard a lot of good things on the call, but I actually thought the call wasn't that bad. And really not much better or worse than some recent previous ones. Mind you, I sold my relatively few remaining MNKD shares some months ago in the $1.80 range. Given how the overall markets behaved today, I thought MNKD stock held up reasonably well all things considered. |
|
|
|
Post by sweedee79 on May 7, 2019 21:21:39 GMT -5
People are overreacting to the call. Wasn't especially great but the people that are calling for mc's head don't have a clue. Don't forget the mess he inherited when he became ceo and where we would be without him today. What we are doing here isn't about just selling another drug, we are asking endo's, who have been doing basically the same thing for the last 20 years to try something completely new. Afrezza, is a life altering drug, but one that is deeply misunderstood in the medical community and isn't going to sell itself. EV's didn't sell themselves either. The tech was around decades ago and it is just now getting a strong foothold in the market. Afrezza has nearly 100 years of habit fighting against it along with 3 bp's worth nearly 300 billion(sanofi, novo, eli.) You have reluctant Dr's who have gone complacent by doing the same thing for decades. Patients, who have been injecting for their entire lives unsure about this new treatment. Insurance companies only looking out for the bottom line and rejecting Afrezza regardless of patient outcomes. BUT, there is progress, albeit not as fast as we would like. listen, we know how good this drug works. We see it all over the place on social media improving peoples lives. It's simply gonna take time. Now, i'm in this for the longhaul, so i'm going to sit back and watch mike and co turn this little snowball into a fucking avalanche. I'm sure glad Mike has the job and not me... !!! He is definitely up against BP.. and there is no doubt in my mind that everything that could be done to kill Afrezza has happened.. Mike has done a lot.. and I hear he doesn't sleep.. maybe he is just getting tired.. gotta have some compassion too..I don't agree with the people calling for Mike's head.either. that's terrible.. |
|
